CONSERVATION STRATEGY Clause Samples

The Conservation Strategy clause outlines the specific measures and plans that parties agree to implement in order to protect and manage natural resources or habitats affected by their activities. Typically, this clause details the actions required, such as habitat restoration, species monitoring, or sustainable resource use, and may assign responsibilities or set timelines for achieving conservation goals. Its core practical function is to ensure that environmental impacts are proactively addressed and mitigated, thereby promoting sustainable practices and compliance with regulatory or ethical standards.
CONSERVATION STRATEGY. Chapters 5, 6, 7, 8.10, and 10.2.1 of the HCP/NCCP describe a Conservation Strategy that includes: the biological goals and objectives of the HCP/NCCP; avoidance and minimization measures to reduce impacts resulting from Covered Activities; land acquisition and assembly of the Preserve System; Preserve System management that includes habitat creation, enhancement and restoration and species population enhancement; Plan Area monitoring and reporting; and adaptive management. As further provided in this Agreement, the HCP/NCCP and the Permits, the Implementing Entity, other Permittees and Third Party Participants are each responsible to implement every applicable Conservation Measure and other measures described in the HCP/NCCP when engaging in Covered Activities and when otherwise required, as they may be modified through adaptive management, whether or not such measures are specifically referenced in this Agreement. For the purposes of this Agreement, all of these measures are collectively referred to as the “Conservation Strategy.”
View SourceView Similar (3)
CONSERVATION STRATEGY. 6.1 The MSHCP is intended to conserve adequate habitat in an unfragmented manner to provide for the protection and security of long-term viable populations of the species that are either currently listed as threatened or endangered, are proposed for listing, or are believed to have a high probability of being proposed for listing in the future if not protected by the Plan. The MSHCP is intended to preserve biological diversity as well as maintain the quality of life within the Coachella Valley and surrounding mountains by conserving species and their associated habitats and coordinating, streamlining and planning Development. By adopting this regional approach, the MSHCP will result in much greater and more biologically effective Habitat and species Conservation than a project-by-project approach could produce. The MSHCP is intended to proactively address requirements of the state and federal ESAs to avoid disruption of economic development activities in the Plan Area. 6.2 The MSHCP provides a broad Conservation Strategy, which will be implemented generally through the following: A. As set forth in Section 4.0 of the MSHCP, the MSHCP Reserve System shall be approximately 745,900 acres and will consist of Existing Conservation Lands, lands conserved through Complementary Conservation and Additional Conservation Lands. The MSHCP Reserve System is divided into 21 Conservation Areas that provide Core and other Conserved Habitat for Covered Species, conserve the natural communities B. For each of the Conservation Areas, Conservation Objectives and required measures shall be implemented as set forth in Section 4.3 of the MSHCP. C. New land uses adjacent to or within the MSHCP Conservation Areas shall implement the Land Use Adjacency Guidelines set forth in Section 4.5 of the MSHCP, as applicable. D. The Avoidance, Minimization and Mitigation Measures set forth in Section E. Monitoring and management activities will be undertaken for each of the MSHCP Covered Species. Monitoring and management activities are described in Section 8 of the MSHCP. F. Species-specific Conservation Goals and Objectives shall be implemented for each of the Covered Species in the MSHCP and are set forth in Section 9 of the MSHCP.
View SourceView Similar (2)
CONSERVATION STRATEGY. The Conservation Strategy has been designed to achieve the BDCP’s overall goals of restoring and protecting ecosystem health, water supply, and water quality in the Delta within a stable regulatory framework. The Conservation Strategy has been developed to meet the regulatory standards of Sections 7 and 10 of the ESA and the NCCPA. The BDCP describes the intended biological outcomes of the Conservation Strategy and details the means by which these outcomes will be achieved. The Conservation Strategy includes biological goals and objectives and conservation actions that appropriately minimize and mitigate the potential effects of Covered Activities and Associated Federal Actions on these resources and provides for the conservation and management of Covered Species and the natural communities upon which they depend. The Conservation Strategy also includes comprehensive programs for adaptive management, monitoring, and research. Additional details regarding the BDCP Conservation Strategy are found in Chapter 3 of the BDCP.
View Source
CONSERVATION STRATEGY. The 2020 DSL CCAA is a conservation strategy and suite of Conservation Measures specifically designed to reduce or eliminate threats to an unlisted species on non- Federal property in West Texas and thereby augment viable populations, in the absence of any existing regulatory means to address those threats. This 2020 DSL CCAA’s Conservation Strategy will guide the implementation of the Conservation Measures and Actions. The Conservation Strategy was developed in consultation with the FWS. The Strategy sets goals (desired biological outcome for the species), objectives (conditions necessary for achieving the goal in terms of reduction or elimination of threats), and criteria (values for determining that the objectives have been met).
View Source
CONSERVATION STRATEGY. The 2020 DSL CCAA’s Conservation Strategy will contribute to the conservation of the DSL by reducing or eliminating threats on Enrolled Property and result in a net conservation benefit to the DSL and its habitat. First, the 2020 DSL CCAA generally requires and incentivizes avoidance of High and Intermediate Suitability Habitat for all Covered Activities with certain exceptions. All New Surface Disturbances will be fully mitigated through the Conservation Action program. Second, habitat degradation and fragmentation, which can be among the principal threats to the DSL in Texas, are reduced by the 2020 DSL CCAA. For example, the 2020 DSL CCAA places an emphasis on avoidance of development in high quality habitat and focuses oil and gas development in areas of degraded habitat (e.g., greater than 13 ▇▇▇▇▇ pads/mi2). This emphasis will reduce the creation of new areas of high-density ▇▇▇▇▇ and, thus, minimize habitat degradation and fragmentation. Third, encouraging avoidance of areas of well densities greater than four and less than 13 well pads/mi2 also should minimize development in areas with the potential to become degraded habitat. Fourth, the CCAA includes a Conservation Strategy calling for well pad removal and reclamation that will reduce well densities in marginal areas of degradation. Moreover, the 2020 DSL CCAA emphasizes the use of Conservation Easements and other protections to create contiguous areas of protected High and Intermediate Suitability DSL Habitat, again reducing the areas of high density and fragmentation of DSL Habitat. Additionally, the 2020 DSL CCAA will fund research to better understand the impacts of well density and roads and to determine whether shinnery oak can be established or reestablished in DSL Habitat, and incorporate through adaptive management and changed circumstances, as appropriate, the results of this research to improve conservation outcomes. Finally, the Administrator may consider implementing, in consultation with FWS, a credit system for the acres of DSL Habitat that may be disturbed by sand mining operations under the 16,560 acre disturbance cap. Under such a system a sand mining Participant would be permitted to sell credits for conservation acres of like DSL Habitat in an Enrolled Property to another enrolled sand mining Participant. Among other things, such a credit system would incentivize enrollment by sand mining operators and provide opportunities for DSL Habitat offsets, including in High Priority A...
View Source
CONSERVATION STRATEGY. Restoration
View Source
CONSERVATION STRATEGY. NCCP/HCP Section 6 describes a Conservation Strategy that includes: the biological goals and objectives of the NCCP/HCP; avoidance and minimization measures to reduce impacts resulting from Covered Activities; land acquisition and assembly of the Preserve Area; Preserve Area management that includes habitat creation, enhancement and restoration and species population enhancement; Plan Area monitoring and reporting, and adaptive management; and measures described in this paragraph and elsewhere in this Agreement and the NCCP/HCP that contribute to the conservation of Covered Species. As further provided in this Agreement, the NCCP/HCP and the Permits, the Water Authority shall implement every applicable Conservation Measure and other measures described in the NCCP/HCP (including the species-specific measures described in Appendix B of the NCCP/HCP) when engaging in Covered Activities and when otherwise required, as they may be modified through adaptive management, whether or not such measures are specifically referenced in this Agreement. For the purposes of this Agreement, all of these measures are collectively referred to as the “Conservation Strategy.”
View Source

Related to CONSERVATION STRATEGY

  • HABILITATIVE SERVICES (HABILITATIVE mean healthcare services that help a person keep, learn, or improve skills and functioning for daily living. Examples include therapy for a child who is not walking or talking at the expected age. These services may include physical and occupational therapy, speech therapy and other services performed in a variety of inpatient and/or outpatient settings for people with disabilities. • that provides medical and surgical care for patients who have acute illnesses or injuries; and • is either listed as a hospital by the American Hospital Association (AHA) or accredited by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO).

  • Staff Development As part of their induction, new staff will be made aware of this policy and will be asked to ensure compliance with its procedures at all times.

  • Procurement Planning Prior to the issuance of any invitations to bid for contracts, the proposed procurement plan for the Project shall be furnished to the Association for its review and approval, in accordance with the provisions of paragraph 1 of Appendix 1 to the Guidelines. Procurement of all goods and works shall be undertaken in accordance with such procurement plan as shall have been approved by the Association, and with the provisions of said paragraph 1.

  • Regulatory Affairs From the point in time at which Novartis gives GW notice in writing that it wishes to take on responsibility for Regulatory Filings and Regulatory Approvals in the Territory, Novartis shall be responsible for all interactions with Regulatory Authorities in the Territory with respect to Regulatory Approvals as set forth in this Section 6.1, and including, filing and maintaining any required Regulatory Approvals, seeking necessary permits and/or scheduling or re-scheduling in controlled substance listings or de-scheduling of the Product from controlled substances listings in the Territory. (a) Where required, Novartis (or its applicable Affiliate or Sublicensee) will be responsible for arranging for the Product to be scheduled in any applicable controlled substance schedule(s) in countries in the Territory. GW agrees, without additional consideration, to give all necessary consents, declarations and documentation as are reasonably required to implement the foregoing and to provide Novartis with all assistance reasonably requested by Novartis (including attending meetings with Regulatory Authorities in any such country) for the purpose of arranging for such scheduling. (b) Subject to Section 6.1(g), Novartis (or its applicable Affiliate or Sublicensee) will file and hold all Regulatory Approvals for the Products in countries in the Territory in its own name and on its own behalf. Unless otherwise agreed by the Parties, within ten (10) Business Days following the Effective Date, GW will assign to Novartis all Regulatory Filings with any Regulatory Authority in the Territory at the Effective Date relating to any Product and Novartis will reimburse GW all fees paid by GW to Regulatory Authorities in such countries with respect to the submission of such Regulatory Filings. On request by Novartis, GW will deliver notices of such assignment to the applicable Regulatory Authorities. In addition, GW agrees to give all necessary consents, declarations and documentation as are reasonably required to implement the foregoing. (c) Subject to Sections 4.2 and 6.1(e), Novartis (or its applicable Affiliate or Sublicensee) will be responsible for conducting, at its sole expense, such activities directed towards obtaining and maintaining Regulatory Approvals for Products in the Territory as it determines appropriate in its sole discretion; provided, however, that Novartis agrees to submit Regulatory Filings for Marketing Approvals for a Product in each of the Key Countries. Thereafter, Novartis shall, on a Key Country-by-Key Country basis further prosecute all such Regulatory Filings in the Key Countries in a timely, professional and diligent manner, including by paying all required filing fees promptly and responding to correspondence and requests for further information from Regulatory Authorities in the Key Countries within a reasonable timeframe. Novartis shall share with GW its plans for obtaining Regulatory Approvals in the Key Countries at the first JSC meeting and thereafter shall supply GW with its updated plan from time to time. Novartis shall report its performance against this regulatory plan to the JSC each Calendar Quarter. (d) Novartis will: (A) determine the regulatory plans and strategies for the Products in the Territory; (B) (either itself or through its Affiliates or Sublicensees and subject to Section 6.1(g)) make and own all Regulatory Filings with respect to the Products in the Territory; and (C) will be responsible for obtaining and maintaining Regulatory Approvals with respect to the Products in the Territory in the name of Novartis or its Affiliates or Sublicensees. Accordingly: (i) Novartis, shall at its own cost write, assemble, otherwise prepare and file all Regulatory Filings required to obtain Regulatory Approvals for Products in the Territory; (ii) Novartis shall be the principal contact with all Regulatory Authorities on all matters pertaining to any Product, but shall consult regularly with GW regarding such matters, giving due regard to GW’s views; (iii) Novartis shall provide to GW copies of all substantive correspondence with Regulatory Authorities in the Territory related to any Product, and, to the extent practicable, shall consult with GW in advance of submitting any material correspondence related to any Product to any such Regulatory Authority; (iv) GW shall provide to Novartis copies of all substantive correspondence with the EMA related to any Product and, to the extent practicable, shall consult with Novartis in advance of submitting any material correspondence related to any Product to the EMA in circumstances where such correspondence could reasonably be expected to impact on the Commercialization and/or Regulatory Approvals of any Product in the Territory; (v) Novartis shall provide such notice to GW as is reasonably practicable under the circumstances of upcoming meetings related to any Product with Regulatory Authorities in the Territory. Subject to the consent of the relevant Regulatory Authority, GW shall be entitled to attend any such meetings as an observer, and Novartis may require GW’s attendance at any such meeting it deems to be potentially material; and (vi) Novartis shall pay all filing and maintenance costs of Regulatory Filings and Regulatory Approvals for the Product in the Territory during the Term. (e) GW shall, without additional consideration, fully cooperate with and provide assistance to Novartis in connection with filings to any Regulatory Authority relating to the Product(s) in the Territory in order to obtain or maintain Regulatory Approvals (including Pricing and/or Reimbursement Approvals, where applicable), including by (i) providing Novartis with an electronic copy of the registration dossier for the Product in the European Union as well as providing Novartis with an electronic copy of this registration dossier in eCTD format if and when available in eCTD format, and upon request by Novartis, an electronic copy of a draft of the registration dossier for the Product in the US as soon as such draft is made available to GW (if this draft is made available to GW in eCTD format GW will provide it to Novartis in eCID format); (ii) upon request by Novartis, providing Novartis with draft responses to any requests from Regulatory Authorities in the Territory related to the Development or manufacture of Products (including any requests related to the chemistry manufacturing and controls (CMC) section of any Regulatory Filing); and (iii) executing any required documents, providing access to personnel and providing Novartis with copies of all reasonably required documentation. To the extent requested by Novartis, GW shall also grant or cause to be granted to Novartis and its Affiliates or Sublicensees, within thirty (30) days of receipt of a written request from Novartis, cross-reference rights to any relevant drug master files and other filings submitted by GW or its Affiliates with any Regulatory Authority and any Regulatory Approval for Product issued by any Regulatory Authority to GW or its Affiliates. (f) Subject to Novartis having access to reimbursement data from outside the Territory, data generated by Novartis for reimbursement shall be available for GW and its ex-Territory licensees of the Products to use with respect to the Products outside the Territory. (g) In the event that (A) it is not possible under applicable Laws for Novartis to file for or hold Regulatory Approvals for the Product in any country in the Territory and/or (B) if requested by Novartis in writing to do so, to the extent permitted by applicable Laws and for the duration determined by Novartis, GW will file and/or hold all Regulatory Approvals for the Products in such country, at Novartis’s cost and expense (provided that all such costs and expenses shall be in accordance with a plan and budget agreed in writing by the Parties prior to GW making any such Regulatory Filing), and: (i) GW will be responsible for, and will use diligent efforts in, obtaining and maintaining all Regulatory Approvals necessary for the Commercialization of the Products in the country in question; (ii) GW will provide to Novartis copies of all substantive written communications between GW (or its Affiliates) and any Regulatory Authority in the Territory relating to any Product; (iii) Novartis shall have the right to review and comment upon any Regulatory Filings and correspondence from GW (or its Affiliates) to any Regulatory Authority in the Territory relating to any Product, and GW shall incorporate or address all such comments unless otherwise agreed between the Parties; (iv) GW will request and seek to arrange such meetings and consultations with Regulatory Authorities in the Territory which may be requested by Novartis, with respect to any Product; (v) To the extent permitted by the relevant Regulatory Authorities, Novartis shall have the right to have representatives of Novartis attend and participate in all meetings between GW (or its Affiliates) and any Regulatory Authority in the Territory relating to any Product; it being understood and agreed that to the extent permitted by the relevant Regulatory Authorities, Novartis will lead discussions with any such Regulatory Authority in the Territory. If the applicable Regulatory Authority does not permit Novartis to lead any such discussion, GW will lead the applicable discussions as directed by Novartis; and (vi) Novartis will reimburse GW any and all costs incurred pursuant to the foregoing and in accordance with the agreed plan and budget as follows. Within thirty (30) days after each Calendar Quarter during which GW has incurred any such costs and expenses, GW will provide to Novartis a detailed accounting of all such costs and expenses, and shall submit an invoice to Novartis substantially in the form of Exhibit C with respect to the amount of such costs and expenses. Unless disputed, Novartis shall pay such amount within sixty (60) days after receipt of such invoice. (h) Novartis hereby grants, and undertakes to cause its Affiliates and Sublicensees to grant, to GW and its Affiliates cross-reference rights to any Regulatory Filing for Product submitted by Novartis or its Affiliates or Sublicensees to any Regulatory Authority in the Territory and any Marketing Approval for Product issued by any Regulatory Authority in the Territory to Novartis or its Affiliates or Sublicensees. Novartis shall also grant such cross-reference rights to those of GW’s licensees of the Products for countries outside the Territory for which Novartis, its Affiliates and Sublicensees are granted corresponding cross-reference rights. (i) The Parties will discuss at the JSC the appropriate response to any request received by either Party from a Third Party academic institution to conduct any investigator initiated clinical study of a Product in the Territory. (j) If any information comes into GW’s Control that requires a change to the CMC section of Regulatory Filings or Regulatory Approvals, inside and outside the Territory, to avoid ‘regulatory drift’ GW will inform Novartis in writing of the required change (including by providing the necessary technical documentation in English) and Novartis will file such documentation with the relevant Regulatory Authorities as soon as practicable.

  • Strategy As an organization without operational services (fuel, maintenance, etc.), and in consideration that the majority of potential issues come from boat maintenance whereby the boats are personal property, the predominant strategy will be the minimization of on-site waste. With this approach, the organization will have minimal potential impact on the environment and reduce regulatory risk. To accomplish this, requirements will be established by policy, periodic communications shall occur, and audits will be utilized to provide feedback for improvement.